John Armitage Vertex Pharmaceuticals Inc Transaction History
Egerton Capital (Uk) LLP
- $7.55 Billion
- Q3 2024
A detailed history of John Armitage (Egerton Capital (Uk) LLP) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Egerton Capital (Uk) LLP holds 124,045 shares of VRTX stock, worth $50.3 Million. This represents 0.76% of its overall portfolio holdings.
Number of Shares
124,045Holding current value
$50.3 Million% of portfolio
0.76%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,725Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.9 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.4 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.65 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.79 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.65 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $104B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...